抗体偶联药物研究进展  

Research and development of antibody-drug conjugates

作　　者：周玥[1,2] 刘小宇[1,2] 卢小玲[1,2] 

机构地区：[1]第二军医大学海洋生物医药研究中心,上海200433 [2]第二军医大学基础部生物化学与分子生物学教研室,上海200433

出　　处：《中国海洋药物》2016年第5期89-94,共6页Chinese Journal of Marine Drugs

基　　金：国家高技术研究发展计划项目(2012AA092105);广东省海洋局公益项目(GD2012-D01-001);国家自然科学基金项目(41306197)资助

摘　　要：抗体-药物偶联物(Antibody-drug conjugates,ADCs)由"弹头"药物(细胞毒药物)、抗体以及偶联抗体和药物的偶联链3部分组成,其作为1种新型药物,结合了抗体的靶向特异性和小分子药物的细胞毒作用,已成为当今肿瘤研究领域的热点。根据其细胞毒药物来源可分为陆地与海洋两大类,本文总结了近年来这两大类抗体偶联药物的研究进展,并从靶点的特异性、抗体的亲和力、高效的细胞毒分子及合适的偶联链等方面对ADCs的发展关键进行了简要评述。Antibody-drug conjugates consist of 3main parts which include the＂bullet＂drugs（cytotoxic drugs）,antibodies and the linker connected the antibodies and drugs.As a new type of drug,it combines the targeting specificity of the antibody with the cytotoxic effect of small molecule drugs,thus it has been the research hotspot in the field of cancer research.According to its source of cytotoxic drugs,it could be divided into two types：land-derived drugs and marine-derived ones.In this paper,these two types antibody-drug conjugates were reviewed.Besides,the key technique of ADCs including the specificity of the target,the affinity of antibodies,the high performance of cytotoxic molecules and the appropriate choice of the linker were summarized.

关 键 词：抗体-药物偶联物 单克隆抗体 靶向治疗 

分 类 号：R965[医药卫生—药理学]